Evidence map›Paper›PMID 30675203›Full record

ArticleOncology letters2019

Diagnosis of mesothelioma with deep learning.

Xue Hu, Zebo Yu

Open access · diamondAbstract read
In one paragraph

Article in Oncology letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Molecular Pathology of Lung Cancer.Cold Spring Harbor perspectives in medicine · 2022
    Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Xue HuDepartment of Blood Transfusion, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China.
Zebo YuDepartment of Blood Transfusion, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China.
Chongqing Medical University · CNFirst Affiliated Hospital of Chongqing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malignant mesothelioma (MM) is a rare but aggressive cancer. The definitive diagnosis of MM is critical for effective treatment and has important medicolegal significance. However, the definitive diagnosis of MM is challenging due to its composite epithelial/mesenchymal pattern. The aim of the current study was to develop a deep learning method to automatically diagnose MM. A retrospective analysis of 324 participants with or without MM was performed. Significant features were selected using a genetic algorithm (GA) or a ReliefF algorithm performed in MATLAB software. Subsequently, the current study constructed and trained several models based on a backpropagation (BP) algorithm, extreme learning machine algorithm and stacked sparse autoencoder (SSAE) to diagnose MM. A confusion matrix, F-measure and a receiver operating characteristic (ROC) curve were used to evaluate the performance of each model. A total of 34 potential variables were analyzed, while the GA and ReliefF algorithms selected 19 and 5 effective features, respectively. The selected features were used as the inputs of the three models. SSAE and GA+SSAE demonstrated the highest performance in terms of classification accuracy, specificity, F-measure and the area under the ROC curve. Overall, the GA+SSAE model was the preferred model since it required a shorter CPU time and fewer variables. Therefore, the SSAE with GA feature selection was selected as the most accurate model for the diagnosis of MM. The deep learning methods developed based on the GA+SSAE model may assist physicians with the diagnosis of MM.

Indexed as

deep learningdiagnosismalignant mesotheliomastacked sparse autoencoder

Identifiers

PMID30675203
PMCPMC6341823
OpenAlexW2902078718

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.